DNA sequence encoding Factor VII with an amino acid substitution at Avg-152
US5288629A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Sep 21, 1992 |
| Grant date | Feb 22, 1994 |
| Priority date | — |
| Expiry date | Sep 21, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Factor VII of the coagulation cascade is modified to act as an anticoagulant. Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.